Reference List

1.

Kitazawa T, Esaki K, Tachibana T, et al. Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens. Thromb Haemost. 2017;117(7):1348-1357.


2.

Data on file. Genentech, Inc.


3.

Genentech. Therapeutic antibodies: the next generation. https://www.gene.com/stories/therapeutic-antibodies-the-next-generation. Accessed November 23, 2017.


4.

Sampei Z, Igawa T, Soeda T, et al. Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity. PLoS One. 2013;8(2):e57479.


5.

Jayapal KP, Wlaschin KF, Hu WS, et al. Recombinant protein therapeutics from CHO cells—20 years and counting. Chem Eng Prog. 2007;10(suppl):40-47.


6.

Eloctate [package insert]. Waltham, MA: Bioverativ; 2017. 


7.

Advate [package insert]. Westlake Village, CA: Baxalta; 2016.


8.

Afstyla [package insert]. Marburg, Germany: CSL Behring; 2017. 


9.

Nuwiq [package insert]. Sweden: Octapharma; 2017. 


10.

Kovaltry [package insert]. Whippany, NJ: Bayer HealthCare; 2016. 


11.

Adynovate [package insert]. Westlake Village, CA: Baxalta; 2017.


12.

Novoeight [package insert]. Bagsvaerd, Denmark:Novo Nordisk; 2018. 


13.

Jivi [package insert]. Whippany, NJ: Bayer HealthCare LLC; 2018. 


14.

Mahlangu JN, Oldenburg J, Paz-Preil I, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2018;379(9):811-822.


15.

Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017;377(9):809-818, Protocol.


16.

National Hemophilia Foundation. MASAC update on the approval and availability of the new treatment: emicizumab (Hemlibra), for persons with hemophilia A with inhibitors to factor VIII: interim guidance on acute bleed management and use of laboratory assays. 2017;1-4.


17.

Kruse-Jarres R, Callaghan MU, Croteau SE, et al. Surgical experience in two multicenter, open-label phase 3 studies of emicizumab in persons with hemophilia A with inhibitors (HAVEN 1 and HAVEN 2) [abstract]. Presented at: ASH 59th Annual Meeting of the American Society of Hematology; December 9-12, 2017; Atlanta, GA.